D

ResMed Inc. — Earnings Quality Grade D

RMD · Healthcare

Significant concerns

Revenue
$5.1B
2025
Net Income
$1.4B
2025
Gross Margin
59.4%
Free Cash Flow
$1.7B
01

Screening Summary

15
Passed
0
Watch
2
Failed
-2.61
M-Score
02

Financial Trends

Revenue & Net Income ($B)

Margins (%)

03

18-Point Screening

01

Revenue Quality

A1DSO Change

DSO 67 days, change +1 days YoY

A2AR vs Revenue Growth

AR outpaced revenue for 2 consecutive years

A3Revenue vs CFFO

Revenue 9.8%, CFFO 25.0%. Cash follows revenue

02

Expense Quality

B1Inventory vs COGS

Inventory 12.8% vs COGS 3.0%. Normal

B2CapEx vs Revenue

CapEx growth -12.4% vs revenue 9.8%. Normal

B3SG&A Ratio

SG&A/Gross Profit = 32.4%. Normal

B4Gross Margin

Gross margin 59.4%, change +2.7pp. Stable

03

Cash Flow Quality

C1CFFO vs Net Income

CFFO/NI = 1.25. Profits backed by cash

C2Free Cash Flow

FCF $1.7B, FCF/NI = 1.18

C3Accruals Ratio

Accruals ratio = -4.3%. Low accruals

C4Cash vs Debt

Cash $1.2B covers debt $0.9B

04

Balance Sheet Health

D1Goodwill + Intangibles

Goodwill+Intangibles $3.5B = 59% of equity. Over 50%

D2Leverage

Debt/EBITDA = 0.4x. Healthy

D3Soft Asset Growth

Other assets -34.6% vs revenue 9.8%. Normal

D4Asset Impairment

No write-off data

05

Acquisition Risk

E1Serial Acquirer FCF

FCF after acquisitions positive

E2Goodwill Surge

Goodwill+Intangibles change 6% YoY. Normal

06

Manipulation Score

F1Beneish M-Score

M-Score = -2.61 (< -2.22). Unlikely manipulator

04

Beneish M-Score

Manipulation Probability-2.61
-4.0 Clean-2.22 Grey-1.78 Danger0
1.022
DSRI
AR growing faster than revenue?
0.955
GMI
Gross margin declining?
0.87
AQI
Asset quality deteriorating?
1.098
SGI
Revenue growth rate
0.956
DEPI
Depreciation slowing?
0.984
SGAI
SG&A ratio changing?
-0.0429
TATA
Accruals level
0.877
LVGI
Leverage increasing?
05

Altman Z-Score

8.65
Safe Zone
0 Distress1.102.605.0+ Safe
0.3042
Liquidity
0.744
Cumulative profit
0.2064
Operating efficiency
2.7046
Leverage

Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-09

ResMed Inc. (RMD) 财报排雷评级 D — EarningsGrade